Home | BSAAM's Organizer | BSAAM's Sponsor | London Accommodation Info | Contact Us
AACL AACL AACL AACL
BSAAM Logo
AACL Logo
BSAAM's Anti Ageing Conference London 2018
Follow us on ...
Facebook  Twitter  Instagram
Conference Information
2017 Speaker List and Presentations
Download 2017 Feedback Form (Required for Credits)
Download 2017 Workshop Feedback Form (Required for Credits)
Download 2017 Program
2017 Program
2017 Exhibitors
2017 Pre-Conference Workshops
2017 Exhibitors Form
2017 Peer Review Board Members
   
Delegate Information
2017 VENUE: The Kensington Town Hall - MAP
Nearby London Accommodations
   
A4M Board Certification
  American Board Of Anti-Aging/Regenerative Medicine (ABAARM)
   
Past Conference Information
  2016
2016 Speakers and Presentations
2016 Programme
2016 Exhibitors
2016 Moderators
BSAAM's AACL 2016 Peer Review Board Members
  2015
2015 Speakers and Presentations
2015 Programme
2015 Exhibitors
2015 Moderators
BSAAM's AACL 2015 Peer Review Board Members
  2014
2014 Speakers and Presentations
2014 Programme
2014 Exhibitors
2014 Moderators
2014 Peer Review Board Members
2014 Aesthetic Peer Review Board Members
  2013
2013 Speakers and Presentations
2013 Programme
2013 Exhibitors
2013 Moderators
2013 Peer Review Board Members
2013 Aesthetic Peer Review Board Members
  2012
2012 Speakers and Presentations
2012 Programme
2012 Exhibitors
2012 Moderators
2012 Peer Review Board Members
2012 Aesthetic Peer Review Board Members
  2011
2011 Speakers and Presentations
2011 Programme
2011 Exhibitors
2011 Moderators
2011 Peer Review Board Members
2011 Aesthetic Peer Review Board Members
  2010
2010 Conference Manual
2010 Speakers and Presentations
2010 Programme
2010 Exhibitors
2010 Moderators
2010 Peer Review Board Members
2010 Aesthetic Peer Review Board Members
  2009
Programme for the 2009
Exhibitors for the 2009
Speakers for the 2009
2009 Peer Review Board Members
2009 Aesthetic Peer Review Board Members
  2008
Programme for 2008
Exhibitors for 2008
Speakers for 2008
2008 Peer Review Board Members
2008 Aesthetic Peer Review Board Members
  2007
  2007 Speaker List
2007 Speaker Programme
  Pre Conference Workshops
Sept 12 Pre-Conference Workshop Programme
Sept 13 Pre-Conference Workshop Programme
  2007 Peer Review Board Members
  Exhibitors for 2007
  2006
  3rd Annual Anti-Ageing Conference Manual (2006)
  Programme for 2006
  ISRM2006 Scientific Board Members
  2006 Peer Review Board Members
  Exhibitors 2006
  2005
  Post Review of 2005
  Remarks about 2005
  Peer Review Board of 2005
  Past Speakers 2005
  2004
  Past Speakers 2004
  2002
  Past Speakers Monte Carlo 2002
   
BSAAM's AACL Organizer
BSAAM
BSAAM Affiliates
waaam
   
   
A4M
   
wosaam
AACL Supporters
HB Health
www.hbhealth.com
   
CPD
   
  BANT
   
 
   
 
   
  Sun Chlorella
   
 
   
enerzona
   
BHMA
   
WOCPM
   
FACE
   
IAAS
   
Dole
   
 
   
 
   
   

AACL 2007 Speaker

BirkmayerProfessor George Birkmayer MD PhD
Ph.D. in Biochemistry, University of Vienna, Austria
M.D. from the University of Munich
Associate Professor for Cell Biology, University of Munich,
Research Fellow with Prof. Michael  Bishop, Dept. Microbiology, UCSF
in 1976. Guest Lecturer at Universities in New York, Philadelphia, Montreal
Since 1982 Professor for Medical Chemistry, University of Graz, Austria
and Medical director of the Birkmayer Laboratories, Vienna, Austria.
Since 1989 he is a visiting Professor at the Universities of Beijing, Guangzhou and Xi’An(China). He is a Fellow of the American College of Nutrition and since 2005 President of the Int. Academy of Tumour Marker Oncology(IATMO), New York.

Professor George Birkmayer, M.D.,Ph.D, discovered the therapeutic effect of NADH (Coenzyme-1) and developed the stabilized orally absorbable form of NADH. Using this formulation he has treated thousands of patients suffering from Parkinson, Alzheimer, depression, CFS, cancer and diabetes. He is the author of more than 150 scientific publications and a member of the editorial board of a number of scientific journals.

2007 - COENZYME 1 (NADH): THE ONLY REAL FUEL FOR CELLULAR ENERGY WITH A SCIENTFICALLY PROVEN ANTI-AGING EFFECT.

Coenzyme-1 (N.A.D.H.) is one of the  most  important  coenzyme  catalyzing
more  than a thousand of metabolic reactions in the human body, the most
important  of which  is the production of  ATP (Adenosin-Tri-Phosphate)
The more ATP energy a cell  has  available  the better it can function and
the   longer  it can live. The question  is  can  we  increase  the ATP production
in  the cells by  exposing them to  coenzyme-1 (NADH).  The answer is yes, we can,
as   has been shown  on isolated heart cells.  When hearts cells are incubated
with   NADH  a 30% increase in ATP production  is observed (1). Due to this the  
vitality and lifespan of these heart cells  are increased.  (
The  same observation  was made  with red   blood cells.  This  discovery  has
 Implications  for the shelf life of  blood donation  and  also for the extension of
 preservation time of transplantable organs .
A  patent  for  this effect of NADH is pending.  This heart cell  system  allows to test
other   coenzymes  and substances for which an energy increasing effect has been claimed.  From all the substances tested so far  including  NAD (the oxidized form of NADH), Nicotinamide (Vitamine B3), Coenzyme Q10, Creatine, Carnitine , Caffeine  only
NADH  does  increase  ATP production in these cells.
NADH as biological form of hydrogen is a very sensitive substance which degrades
rapidly   even in dry state when blended with lactose the most common ingredient of
drugs.  The author succeeded in  stabilizing  NADH  and transposing it into a  tablet form
in  which NADH is stable for  at least 2 years.  This formulation, patented world-wide   is  commercially available under the brand name ENADA™.
Based on the patent protection of this product   numerous   GCP studies have been performed
in the U.S. as well as in Europe. In  an  FDA  approved  double-blind placebo controlled study
it was found that  NADH  leads to an improvement of certain cognitive functions in patients
with  Alzheimer dementia. (2) . Another FDA  approved  double blind study  with patients suffering  from CFS (Chronic Fatigue Syndrome)  revealed  more than 80 % of the patients
were  relieved  from their fatigue after a 6 month treatment period with 10 mg NADH per day.

In a  further study  the  effect  of NADH  on cognitive performance  of healthy middle aged individuals  after sleep deprivation for 24 hours  was tested   at Cornell University.
Subjects taking 20 mg of  NADH did not only better in terms of cognitive performance than the placebo subjects  but  did more than 3 times better than the same subjects  at base line,
after  a full night sleep (3). In other words,   NADH  enhances cognitive performance in healthy  individuals  and  due to its energy-increasing effect for the brain it  may  prevent  MCI (Mild Cognitive Impairment)  as well as   Alzheimer dementia.
As  most  cancer  cells  exhibit   an ATP deficiency  and   NADH  can increase ATP energy in  cells  this coenzyme was given to  cancer patients in an open label trial.  17  prostate cancer
patients with  pathologically proven carcinoma have been cured in  3 to 5 months with a daily dose of  40 mg NADH.  A  number  of  patients  with  mammary carcinoma  and
small cell lung cancer  have  been cured  in between  6 months with the  same daily dose
of  NADH.(4) More than  6o  cancer  patients have been treated so far with NADH most of them are disease free or  show no  tumour progression.  The   increase in physical  and  mental  energy  was  reported  from  all the cancer patients  taking NADH.
The   mechanism of action of  NADH  is  based on  the   elevation of the intracellular ATP.
Hence   NADH   may   be  a reasonable approach  for many  ailments particular those based
on   mitochondrial  dysfunctions.
   
References:
(1)  Pelzmann, B., et al., Brit.J.Pharm.2003, 139, 749-754
(2)  Demarin, V. et al. Drugs Exptl. Clin. Res. 2004 ,XXX , 27-33
(3)  Moline, ML. Et al. Abstr.1st Int. Conf. Mech. Action Nutraceuticals 2001
(4)  Forsyth, L.M., et al. Ann.Allergy Asthma  Immun. 1999, 82, 185-191
(5)  Birkmayer, G., and Zhang, J. in Bagchi,D. and Preuss H.G. “Phytopharmaceuticals
       in  Cancer  Chemoprevention , CRC Press 2005, 541-554

 

Home | BSAAM's Organizer | BSAAM's Sponsor | London Accommodation Info | Contact Us
BSAAM's Anti Ageing Conference London, 38 Regent on the River
William Morris Way London SW6 2UT, United Kingdom
Tel: +44 (0)79 7317 3478  Fax: +44 (0)20 7491 0410
Emails :
london@antiageingconference.com
mariasomers@bsaam.com